Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 double-blind, placebo-controlled trial assessing the safety, tolerability and PK of islatravir administered using a drug-eluting implant placed subdermally in healthy participants

Next Previous
X
Search
Trial Profile

Phase 1 double-blind, placebo-controlled trial assessing the safety, tolerability and PK of islatravir administered using a drug-eluting implant placed subdermally in healthy participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Islatravir (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms IMPLANT
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 29 Nov 2022 Results assessing the safety, tolerability and pharmacokinetics of islatravir Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection published in the JAIDS
    • 15 Mar 2021 New trial record
    • 10 Mar 2021 Data from this study and from in vitro assessments of the ISL implants in establishing a threshold islatravir-TP concentration of 0.05 pmol/million cells in PBMCs, presented at the 28th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top